Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022;4(1):29-33.
doi: 10.33696/immunology.4.130.

Commentary: Experimental Mouse Models of Invasive Candidiasis Caused by Candida auris and Other Medically Important Candida Species

Affiliations

Commentary: Experimental Mouse Models of Invasive Candidiasis Caused by Candida auris and Other Medically Important Candida Species

Hong Xin. J Cell Immunol. 2022.

Abstract

The study ""Experimental Mouse Models of Disseminated Candida auris Infection" provides the first insight into the critical role of C5 in the host antimicrobial defense to disseminated candidiasis caused by C. auris. This study also establishes an inbred A/J mouse model of systemic C. auris infection without drug-induced immunosuppression. C. auris has become the first fungal pathogen causing global public health threat due to its multidrug resistance (MDR) and persistence in hospital and nursing home settings. Currently, as compared to C. albicans, very limited animal models are available to study the progression of non-albicans Candida (NAC) species including C. auris. We have successfully established immunosuppressed C57BL/6, BALB/c and A/J murine models of disseminated candidiasis caused by five clinically significant Candida species: C. albicans, C. glabrata, C. tropicalis, C. parapsilosis and C. auris. Here we also report updated progress of some important mouse models for C. auris infection in the field. These valuable mouse models can be used for the assessment of antifungal drugs, evaluation of potential vaccines and monoclonal antibodies (mAbs) to protect before and after candidiasis, and comparison of pathogenicity of different Candida species.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Dimopoulos G, Ntziora F, Rachiotis G, Armaganidis A, Falagas ME. Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome. Anesthesia & Analgesia. 2008. Feb 1;106(2):523–9. - PubMed
    1. Pappas PG, Rex JH, Lee J, Hamill RJ, Larsen RA, Powderly W, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clinical Infectious Diseases. 2003. Sep 1;37(5):634–43. - PubMed
    1. Viudes A, Peman J, Canton E, Ubeda P, Lopez-Ribot J, Gobernado M. Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. European Journal of Clinical Microbiology and Infectious Diseases. 2002. Nov;21(11):767–74. - PubMed
    1. Krcmery V, Barnes AJ. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. Journal of Hospital Infection. 2002. Apr 1;50(4):243–60. - PubMed
    1. Johnson CJ, Davis JM, Huttenlocher A, Kernien JF, Nett JE. Emerging fungal pathogen Candida auris evades neutrophil attack. MBio. 2018. Aug 21;9(4):e01403–18. - PMC - PubMed

LinkOut - more resources